Form 4: Arvinas CEO John Houston Reports Stock and Option Awards

Arvinas CEO John Houston reports the acquisition of restricted stock units and stock options, signaling continued alignment with the company's long-term performance.

Summary

• On February 13, 2025, Arvinas CEO John G. Houston was granted 152,000 restricted stock units (RSUs) and an option to purchase 232,000 shares of Arvinas common stock.
• The RSUs will vest over four years, with 25% vesting annually on February 13th from 2026 to 2029, contingent upon continued service.
• The stock options, with an exercise price of $17.67, also vest over four years, with 1/4 vesting on February 13, 2026, and the remainder in equal monthly installments until February 13, 2029, subject to continued service.
• Following these transactions, Houston directly owns 1,188,681 shares of Arvinas common stock and options to purchase 232,000 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The grant of stock options and RSUs to the CEO is a standard practice and indicates confidence in the company's future performance. The vesting schedule promotes long-term alignment.

Positives

• The grant of RSUs and stock options to the CEO aligns his interests with the long-term success of Arvinas.
• The vesting schedules incentivize continued service and commitment from the CEO.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the equity grants suggest an expectation of continued growth and value creation.

Industry Context

Equity grants are a common practice in the biotechnology industry to incentivize and retain key executives. The size and vesting schedule of these grants are typical for a CEO of a company like Arvinas.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation components for executives in publicly traded biotech companies.
• Companies like Amgen, Gilead, and Biogen also utilize similar equity-based compensation plans to align executive incentives with shareholder value.
• The vesting schedules are also typical, encouraging long-term commitment and performance.

Stakeholder Impact

• The equity grants align the CEO's interests with those of shareholders, potentially leading to increased shareholder value.
• The grants also serve as an incentive for the CEO to remain with the company, providing stability and leadership.

Key Dates

Keywords

Arvinas, John Houston, CEO, stock options, restricted stock units, RSU, ARVN, beneficial ownership, Form 4